Discover trends, market shifts, and competitive outlooks for the predictive biomarkers industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Predictive Biomarkers Market Growth Evolved From 2024 To 2025, And What’s Ahead?

There has been a consistent expansion in the size of the predictive biomarkers market in the past few years. The market size is set to increase from $20.05 billion in 2024 to $20.96 billion in 2025, projecting a compound annual growth rate (CAGR) of 4.5%. Various factors contributing to this growth during the historic period include the surge in research and development investments, improvement in healthcare infrastructure, partnerships between educational institutes and the industry, an upward trend in the occurrence of cancer and genetic diseases, and the escalated usage of biomarkers in the process of drug development.

It is projected that within several years, the predictive biomarkers market size will experience a consistent expansion. The market is anticipated to climb to $24.67 billion by 2029, with a compound annual growth rate (CAGR) of 4.2%. The progression during the forecast period can be linked to the growing acceptance of precision medicine, heightened attention towards preventive healthcare, an uptick in healthcare spending, additional investments in biomarker-focused diagnostics, the establishment of more biobanks and tissue repositories, and an increase in global health consciousness. The dominant trends expected in the forecast period encompass the incorporation of artificial intelligence into biomarker analysis, the advent of non-invasive biomarker testing, progress in digital health tools based on biomarkers, advancements in single-cell sequencing technologies, the development of real-time biosensing and monitoring systems, and improvements in bioinformatics tools for data integration.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20595&type=smp

What Are the Core Growth Drivers Propelling the Predictive Biomarkers Market Forward?

The predictive biomarkers market’s expansion is anticipated to be driven by the surge in cancer cases. Cancer, a disease typified by unchecked cell growth that can spread to other parts of the body, is primarily on the rise due to the aging population, lifestyle modifications, and increased exposure to risk factors like tobacco use, unhealthy dietary habits, and environmental toxins. Predictive biomarkers in cancer assist in recognizing patients who are likely to respond positively to certain treatments, thereby facilitating personalized and more efficient therapy. For example, as stated in a report from the International Agency for Research on Cancer (IARC), a specialized cancer research agency under the World Health Organization (WHO) based in France, in April 2024 there were almost 20 million new cancer cases and roughly 10 million cancer-related fatalities in 2022. Moreover, it is projected that the yearly count of new cancer cases will reach 35 million by 2050, signifying a 77% climb from the 2022 figures. Hence, the escalating occurrence of cancer will fuel the predictive biomarkers market’s growth.

What Segment Types Define the Predictive Biomarkers Market Structure?

The predictive biomarkers market covered in this report is segmented –

1) By Indication: Cancer, Metabolic Disease, Cardiovascular Disorder, Immunological Disorder, Other Indications

2) By Application: Screening, Analysis, Diagnosis, Prediction, Monitoring

3) By End User: Diagnostic Centers, Contract Research Organizations, Academic Research Institutes, Pharms And Biotech Companies, Other End Users

Subsegments:

1) By Cancer: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Ovarian Cancer, Leukemia And Lymphoma, Melanoma, Pancreatic Cancer, Kidney Cancer, Head And Neck Cancer

2) By Metabolic Disease: Type 1 and Type 2 Diabetes, Obesity, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease (NAFLD), Dyslipidemia, Insulin Resistance

3) By Cardiovascular Disorder: Atherosclerosis, Coronary Artery Disease, Heart Failure, Myocardial Infarction (Heart Attack), Arrhythmia, Hypertension, Stroke, Peripheral Arterial Disease

4) By Immunological Disorder: Autoimmune Diseases, Inflammatory Bowel Disease (IBD), Multiple Sclerosis, Psoriasis, Allergic Diseases, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Immunodeficiency Disorders

5) By Other Indications: Neurological Disorders, Infectious Diseases, Renal Diseases, Osteoarthritis, Genetic Disorders, Respiratory Disorders

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20595&type=smp

Which Geographic Areas Hold the Strongest Growth Potential in the Predictive Biomarkers Market?

North America was the largest region in the predictive biomarkers market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Predictive Biomarkers Market?

Leading firms in the predictive biomarkers market are investing in accelerating biomarker development through innovative technology, including AI-facilitated biomarker discovery. This strategy empowers these firms to stay competitive by delivering more customized and efficient treatments quickly. AI-facilitated biomarker discovery allows for large and intricate dataset analysis, potentially identifying predictive biomarkers that traditional techniques may not detect. For instance, Scipher Medicine, Inc., a US-based firm specializing in precision immunology, initiated a PRoBeNet (Predictive Response Biomarkers using Network Medicine) in July 2024. Its primary objective is to speed up the development of predictive response biomarkers for complex diseases through AI and network biology. PRoBeNet detects therapy response biomarkers by merging therapy-targeted proteins and disease-specific molecular patterns. Its effectiveness has been proven in autoimmune diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease, and it shows promise for application in other complex diseases and drug development stages.

View the full report here:

https://www.thebusinessresearchcompany.com/report/predictive-biomarkers-global-market-report

What Is the Definition of the Predictive Biomarkers Market?

Predictive biomarkers refer to biological indicators that help predict an individual’s likelihood of developing a disease or their response to a specific treatment. They can be genetic, proteomic, or molecular markers that provide insights into disease susceptibility or treatment efficacy and the advantage of tailoring treatments to individual patients, enhancing the effectiveness of interventions, and potentially reducing adverse effects by identifying those most likely to benefit from specific therapies.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20595

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model